Our Values
At Cutis, we are driven by a strong set of core values that guide our every action and decision. These values form the foundation of our commitment to provide exceptional dermatological care. Our values revolve around patient-centered care, excellence, professionalism, innovation, and collaboration.
Patient-centred
We believe in treating each patient with respect, dignity, and empathy. Care is tailored to each individual patient’s need.
Excellence
We aim to provide the highest quality care and services.
Professionalism
We maintain the highest standards of professionalism in all our interactions, both with patients and colleagues.
Innovation
We embrace innovation and strive to be at the forefront of new developments in Dermatological research and technology.
Collaboration
We believe in working collaboratively with our patients, their families, their employers and other healthcare professionals to achieve the best possible outcomes.
The Cutis leadership team
Dr Dan Glass
MBChB PhD FRCP
Medical Director
A UK trained Consultant Dermatologist who is a registered skin specialist with the General Medical Council. Dr Glass has specialised in Dermatology for almost 20 years.
In addition to a busy clinical practice looking after over 30000 patients; Dr Glass has actively been involved in skin disease research since 1993. His clinical practice is complemented
by the research he has carried out into the genetic basis of development of melanoma skin cancer and skin ageing. Dr Glass always aims to provide the patients in his clinic with the highest quality patient centred care.
Kim Batcheler
MBA
Director
Kim co-founded Delta Technology in 2007 to become a largescale
IT outsourcing company with offices in the US, Europe, and Asia, servicing multiple Fortune 500 companies.
Through a diverse investment portfolio, Kim has created several new companies ranging from app development to medical life-sciences. His investments include Opus Biological, the UK’s first MHRA compliant Mesenchymal Stem Cell clinic. In addition, he has controlling interests in investments in the United Arab Emirates and in the United States in the technology sectors.